Hemophilia A and B

What changes during this transition

Hemophilia is the X-linked recessive bleeding disorder family caused by clotting factor deficiency: HEMOPHILIA A (factor VIII deficiency, F8 gene at Xq28, ~80% of cases, incidence ~1/5,000-10,000 male births) and HEMOPHILIA B (factor IX deficiency, F9 gene at Xq27.1, ~20% of cases, ~1/25,000-40,000 male births). Severity is classified by residual factor activity — severe (<1%, spontaneous bleeds with hemarthroses + intracranial hemorrhage risk), moderate (1-5%, bleeding with minor trauma), mild (5-40%, often undiagnosed until surgical or dental challenge). Untreated severe disease produces recurrent joint bleeds → hemophilic arthropathy (target joints: knees, ankles, elbows) → progressive joint destruction; muscle hematomas with compartment syndrome risk; oropharyngeal hematoma; GI/GU bleeding; and intracranial hemorrhage as the leading cause of mortality, especially in infants and after trauma. Carrier females, often described as asymptomatic, frequently have lower FVIII/FIX activity (X-inactivation produces variable expression) and meaningful bleeding — particularly menorrhagia and postpartum hemorrhage; obligate carriers include daughters of affected males. Diagnostics: prolonged aPTT corrected by mixing study, FVIII/FIX activity assays, F8/F9 genetic testing, and inhibitor screening via Bethesda assay — neutralizing anti-FVIII or anti-FIX antibodies develop in ~30% of severe hemophilia A and ~5% of severe hemophilia B and are the major treatment-era complication. Standard of care has been transformed twice. First transformation (1990s-2010s): recombinant or plasma-derived factor concentrate replacement moved from on-demand to prophylactic, with extended half-life products (Eloctate/rFVIIIFc, Alprolix/rFIXFc, Adynovate, Idelvion, Rebinyn) reducing infusion frequency from 2-3x/week to weekly. Second transformation (2017-2025): EMICIZUMAB (Hemlibra, Roche/Genentech) — a bispecific antibody that binds FIX/FIXa and FX/FXa to mimic FVIIIa activity, FDA-approved November 2017 initially for hemophilia A with inhibitors, expanded October 2018 to all hemophilia A regardless of inhibitor status, with SC dosing weekly/Q2wk/Q4wk producing ~96% bleeding reduction in HAVEN and HOHOEMI trials. EFANESOCTOCOG ALFA (Altuviiio/Altuvoct, Sanofi/Sobi), the ultra-EHL FVIII, FDA-approved February 2023 with once-weekly dosing achieving near-normal hemostasis (XTEND-1, XTEND-Kids, ELECTIVE-A). FITUSIRAN (Qfitlia, Alnylam/Sanofi), an siRNA targeting antithrombin to rebalance coagulation, FDA-approved March 2025 for hemophilia A and B with or without inhibitors, SC monthly, ~70% bleed reduction in ATLAS. CONCIZUMAB (Alhemo, Novo Nordisk), an anti-TFPI monoclonal antibody, FDA-approved December 2024 for hemophilia A or B with inhibitors ≥12 years, SC daily (explorer8). The gene therapy era opened in parallel: HEMGENIX (etranacogene dezaparvovec, CSL Behring), an AAV5-FIX therapy, FDA-approved November 2022 for adult severe hemophilia B (HOPE-B, ~$3.5M list). ROCTAVIAN (valoctocogene roxaparvovec, BioMarin), an AAV5-FVIII therapy, FDA-approved June 2023 for adult severe hemophilia A (GENEr8-1, ~$2.9M list, variable durability). BEQVEZ (fidanacogene elaparvovec, Pfizer), an AAV-FIX therapy, FDA-approved April 2024 for adult severe hemophilia B (BENEGENE-2). Multiple additional gene therapies in trials. Comprehensive care runs through hemophilia treatment centers (HTCs) — multidisciplinary teams (hematology, orthopedics, physical therapy, dentistry, psychology, genetics, nursing) — within the World Federation of Hemophilia (WFH, wfh.org) international network alongside the National Hemophilia Foundation, Hemophilia Federation of America, the Hemophilia Society UK, and national societies internationally; WFH 2020 guidelines, MASAC recommendations, and the WFH Annual Global Survey and EUHASS track the international registry. Global access disparities are stark: high-income countries approach 100% factor coverage while many LMICs have limited access, and the gene therapy and bispecific-antibody era is widening that gap until access programs catch up. The community also carries traumatic memory from the contaminated-plasma era (HIV and HCV transmission via plasma-derived factor products in the 1980s) — a context that shapes how new biologic therapies are received. The peptide-community angle is narrow and indirect. Community peptides reach hemophilia patients almost exclusively through general 'healing' framing (BPC-157 for joint and tissue repair) or general-wellness framing (NMN for aging, CJC-1295/ipamorelin/tesamorelin for body composition, semaglutide for the rising obesity rates that prophylaxis-era longevity has produced). None of these have been characterized in F8 or F9 deficiency at any factor activity level. Two load-bearing safety considerations cut across all of them: (1) the injection itself is a bleed-risk event in severe disease, requiring HTC-set factor-coverage protocols and route restrictions (IM is contraindicated; SC only with timing relative to prophylaxis dose); (2) the disease-modifying therapies already in the patient's regimen (Hemlibra, Altuviiio, Qfitlia, Alhemo, gene-therapy follow-up) have not been studied for interaction with community peptides, and that uncertainty is itself the answer. This entry deliberately does not elevate community peptides as discovery cards — the standard-of-care peptide- and protein-class therapies (emicizumab, efanesoctocog alfa, fitusiran, concizumab) and gene therapies (Roctavian, Hemgenix, Beqvez) are the dominant interventions, and they are managed through HTCs, not through the peptide community. Carrier females, pediatric patients, post-gene-therapy recipients tracking durability and ALT elevations, and patients living with HIV/HCV from the contaminated-plasma era each carry additional layers of coordination that further argue for HTC-routed care rather than peptide-community improvisation. Eighty-first deliberate non-elevation of community peptides.